Definition and epidemiology
Mania is a syndrome of abnormally and persistently elevated, expansive, or irritable mood accompanied by increased goal-directed activity or energy, present for at least one week nearly every day, most of the day (DSM-5-TR), or of any duration if it necessitates hospitalization. Hypomania is a milder, shorter (minimum 4 days) variant without marked impairment, psychosis, or hospitalization.
- Lifetime prevalence of bipolar I disorder is approximately 1%, with roughly equal rates in men and women.
- Mean age of onset is in the late teens to early twenties; onset after age 50 should prompt a search for a secondary (organic) cause.
- A single manic episode is sufficient to diagnose bipolar I disorder, even without a prior depressive episode.
- Men tend to have more manic episodes; women tend to have more depressive and mixed episodes and more rapid cycling.
- A single manic episode is enough to diagnose bipolar I disorder.
- Hypomania lacks marked impairment, psychosis, and hospitalization; mania has at least one of these.
- Decreased need for sleep (feeling rested on little sleep), not insomnia, is characteristic of mania.
- Late-onset mania (after age 50) should prompt workup for a secondary/organic cause.
- Lithium is first-line for maintenance and has the best evidence for suicide risk reduction in bipolar disorder, but has a narrow therapeutic index requiring regular serum level monitoring.
- Valproate carries black box warnings for hepatotoxicity, pancreatitis, and fetal risk (teratogenicity).
- Avoid antidepressant monotherapy in bipolar disorder due to risk of inducing mania or mixed states.
- Check TSH and urine toxicology to exclude thyrotoxicosis and stimulant use before diagnosing primary mania.
Etiology and risk factors
Mania is best understood as a final common clinical syndrome with multiple contributing causes.
Primary (psychiatric)
- Bipolar I disorder (classic cause of full manic episodes)
- Bipolar II disorder presents with hypomania, not full mania
- Schizoaffective disorder, bipolar type
Risk factors
- Strong genetic loading: heritability estimated around 60-85%; first-degree relatives have markedly increased risk
- Family history of bipolar disorder or mood disorders
- Postpartum period (risk of postpartum mania/psychosis)
- Sleep deprivation and disrupted circadian rhythm
- Psychosocial stressors, though mania can also arise without an obvious trigger
Secondary ("organic") causes to exclude, especially with late-onset or atypical presentations
- Substance intoxication: stimulants (cocaine, amphetamines), hallucinogens
- Medications: corticosteroids, levodopa, some antidepressants (treatment-emergent mania/hypomania), interferon, thyroid hormone excess
- Medical conditions: hyperthyroidism, Cushing syndrome, CNS lesions (frontal/right-sided), multiple sclerosis, HIV/CNS infection, stroke
- Withdrawal states (e.g., from sedatives in some cases)
Pathophysiology
The precise mechanism is not fully established, but converging evidence points to several contributing processes.
- Monoamine dysregulation: excess dopaminergic and noradrenergic signaling is implicated in manic symptoms, analogous to the opposite pattern seen in depression
- Circadian and sleep system dysfunction: disrupted sleep-wake regulation can both trigger and perpetuate episodes
- Neuroimaging findings include altered prefrontal-limbic connectivity, with reduced top-down prefrontal regulation of amygdala and striatal reward circuits, contributing to impulsivity and emotional dysregulation
- Kindling hypothesis: repeated mood episodes may lower the threshold for future episodes, partly explaining why relapse risk increases with each untreated episode
- Genetic contributions involve polygenic risk affecting ion channels, circadian genes, and neurotransmitter signaling pathways
Clinical features
Mania affects mood, cognition, behavior, and physiology simultaneously. A useful mnemonic for core features is DIGFAST (see Mnemonic section).
- Mood: elevated, euphoric, or irritable; mood lability
- Decreased need for sleep (not insomnia — the patient feels rested after very little sleep)
- Grandiosity or inflated self-esteem (may become delusional)
- Pressured, rapid speech; may be difficult to interrupt
- Flight of ideas or subjective sense that thoughts are racing
- Distractibility, poor concentration
- Increase in goal-directed activity (social, work, sexual) or psychomotor agitation
- Excessive involvement in high-risk activities: spending sprees, sexual indiscretions, risky investments, reckless driving
- Impaired insight is common; patients often do not perceive themselves as ill
- Psychotic features (mood-congruent delusions of grandeur, less commonly hallucinations) occur in a substantial proportion of severe episodes
- Severe cases may require hospitalization for safety, impulsivity, or psychosis
Diagnosis
Diagnosis is clinical, based on history (often corroborated by family/collateral informants, since insight is impaired) and mental status examination.
DSM-5-TR core criteria (manic episode)
- Abnormally elevated, expansive, or irritable mood AND increased energy/activity, present most of the day, nearly every day, for at least 1 week (or any duration if hospitalization required)
- At least 3 additional symptoms (4 if mood is only irritable) from the DIGFAST list
- Marked impairment in functioning, psychotic features, or need for hospitalization
- Not attributable to a substance or another medical condition
Workup to exclude secondary causes
| Test | Purpose |
|---|---|
| TSH, free T4 | Rule out hyperthyroidism |
| Urine toxicology | Rule out stimulant/substance-induced mania |
| CBC, BMP, LFTs | Baseline before starting mood stabilizers |
| Pregnancy test | Affects treatment choice |
| Brain MRI/CT | If late-onset, atypical, or focal neurologic signs suggest a structural lesion |
| ECG | Baseline if antipsychotics (QT) or lithium being considered |
Mood-stabilizer-specific baseline labs (e.g., renal function and TSH before lithium; liver function before valproate) are obtained prior to initiating treatment.
Differential diagnosis
- Hypomania (bipolar II disorder): similar symptoms but shorter minimum duration (4 days), no marked functional impairment, no psychosis, no hospitalization
- Substance-induced mood disorder: temporally linked to intoxication/withdrawal (stimulants, corticosteroids)
- Schizophrenia or other primary psychotic disorder: psychosis predominates and persists outside mood episodes; mood symptoms are not the primary disturbance
- Attention-deficit/hyperactivity disorder: overlapping distractibility and impulsivity but chronic, not episodic, and without elevated mood or decreased sleep need
- Borderline personality disorder: mood lability is reactive and rapidly shifting (hours), not sustained over days as in mania
- Delirium: fluctuating consciousness and attention, often with an identifiable medical cause, distinguishes it from mania
- Hyperthyroidism: can mimic manic agitation and insomnia; thyroid function tests clarify
- Cyclothymic disorder: chronic, milder mood fluctuations not meeting full criteria for mania or major depression
Management
Management goals are acute stabilization/safety followed by relapse prevention; approach is broadly consistent across WHO, APA, and major European (e.g., CANMAT/ISBD, NICE) guidance, though specifics on agent sequencing vary.
Acute management
- Assess safety first: risk of harm to self/others, impulsivity, and need for hospitalization or involuntary treatment where legally indicated
- Discontinue potential precipitants (e.g., antidepressant monotherapy, stimulants) where feasible
- Pharmacologic options (used alone or in combination), chosen based on severity, prior response, and tolerability:
- Lithium
- Valproate (avoided in women of childbearing potential when possible due to teratogenicity)
- Atypical antipsychotics (e.g., olanzapine, quetiapine, risperidone, aripiprazole)
- Short-term benzodiazepines may be used adjunctively for acute agitation/insomnia
- Severe psychotic or treatment-resistant mania, or mania in pregnancy with high acuity, may warrant electroconvulsive therapy
Boxed safety warnings for key mood stabilizers
- Valproate carries boxed warnings for hepatotoxicity (sometimes fatal, especially in young children and those with mitochondrial disorders), pancreatitis, and fetal risk (neural tube defects and other major malformations); it should be avoided in pregnancy and in women of childbearing potential when alternatives are feasible.
- Lithium has a narrow therapeutic index: toxicity can occur at serum levels close to the therapeutic range, and risk rises sharply with dehydration, renal impairment, or interacting drugs (e.g., NSAIDs, ACE inhibitors, thiazide diuretics). Regular serum lithium level monitoring is required to detect early toxicity and prevent severe or fatal outcomes.
Maintenance / relapse prevention
- Continue a mood stabilizer or atypical antipsychotic long-term; lithium has the strongest evidence for reducing suicide risk
- Psychoeducation, regular sleep-wake schedule, and psychotherapy (e.g., family-focused therapy, cognitive-behavioral approaches) support adherence and relapse prevention
- Avoid antidepressant monotherapy in bipolar disorder due to risk of triggering mania or mixed states; if used for breakthrough depressive episodes, combine with a mood stabilizer
- Regular monitoring of lithium levels, renal and thyroid function (for lithium) or liver function and levels (for valproate)
Complications and prognosis
- Functional impairment: job loss, relationship breakdown, financial and legal problems from impulsive behavior during episodes
- Increased risk of substance use disorders, which worsen course and treatment adherence
- Significantly elevated suicide risk across the bipolar spectrum, particularly during mixed and depressive phases
- Risk of recurrence is high; untreated or inadequately treated patients often experience multiple episodes over a lifetime, with the kindling phenomenon potentially shortening the interval between episodes
- With appropriate long-term maintenance treatment and psychosocial support, many patients achieve good functional recovery, though full symptom remission between episodes is not universal
- Comorbid anxiety disorders are common and worsen overall prognosis
- Treatment-related complications: lithium toxicity (tremor, confusion, renal and thyroid dysfunction over time) and valproate-related hepatotoxicity or pancreatitis both require ongoing lab monitoring to detect early
DIGFAST: Distractibility, Indiscretion (risky behavior), Grandiosity, Flight of ideas, Activity/energy increase, Sleep deficit (decreased need), Talkativeness (pressured speech) — need 3 of these (4 if mood is only irritable) plus elevated/irritable mood and increased energy.
Practice questions
1. A 24-year-old man is brought to the emergency department by his roommate because he has not slept in 5 days but reports feeling full of energy. He has started three new business ventures this week, speaks rapidly and is difficult to interrupt, and insists he will "solve world hunger within the year." He has no significant medical history and urine toxicology is negative. Which of the following is the most likely diagnosis?
2. A 58-year-old woman with no psychiatric history presents with a 3-week history of euphoria, decreased sleep, and impulsive spending. She also reports palpitations, weight loss despite increased appetite, and heat intolerance. On exam she has a fine tremor and tachycardia. Which test should be obtained first to guide diagnosis?
3. A 31-year-old woman with known bipolar I disorder is started on lithium for a manic episode. Which of the following baseline tests is most important to obtain before initiating therapy?
Frequently asked questions
What causes mania?
Mania most commonly arises from bipolar I disorder, which has a strong genetic basis involving dysregulated monoamine signaling and disrupted circadian/sleep systems. It can also be triggered or caused by stimulant use, certain medications (corticosteroids, levodopa), hyperthyroidism, or less commonly a CNS lesion. Sleep deprivation and major stressors can precipitate episodes in people with an underlying vulnerability.
What are the first symptoms of mania?
Early signs often include decreased need for sleep without feeling tired, increased energy and goal-directed activity, and a shift toward elevated, irritable, or expansive mood. Pressured speech, racing thoughts, and increasing impulsivity (spending, risk-taking) frequently follow. Family members often notice the change before the patient does, since insight is typically impaired.
How is mania diagnosed?
Mania is diagnosed clinically using DSM-5-TR criteria: at least one week of elevated/irritable mood and increased energy, plus at least three (or four, if mood is only irritable) additional symptoms such as grandiosity, decreased sleep need, or pressured speech, causing marked impairment, psychosis, or hospitalization. Collateral history is important, and labs/imaging are used to rule out secondary causes like thyroid disease or substance use.
Is mania curable?
Mania itself is not "cured" in the sense of permanent eradication, but acute episodes are treatable and most patients achieve remission of symptoms with mood stabilizers or antipsychotics. Bipolar disorder is a chronic, relapsing condition that requires long-term maintenance treatment to prevent recurrence. Many patients achieve good long-term functional stability with consistent treatment and monitoring.
Mania vs hypomania — what is the difference?
Mania causes marked impairment in functioning, may include psychotic features, and often requires hospitalization, while hypomania does not reach this severity. Mania must last at least one week (or any duration if hospitalized); hypomania requires only four consecutive days. Hypomania occurs in bipolar II disorder, while a full manic episode defines bipolar I disorder.
Key drugs
Related conditions and differentials
Sources and further reading
StatPearls (NCBI Bookshelf)MedlinePlusWHO ICD-10: F30
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.